MRNA in situ hybridization (HistoSonda): A new diagnostic tool for HER2-Status in breast cancer-A multicentric spanish study

Diagnostic Molecular Pathology

Volumn 21, Issue 2, 2012, Pages 84-92

  Bernet, Laia ^a   Martinez Benaclocha, Marcos ^a   Castera, Carles ^a   Cano Muñoz, Rafael ^b   Sevilla, Francisco ^a   Alba, Javier ⁿ   De Dios Barranco, Juan ^c   Cordoba, Alicia ^d   Garcia Caballero, Tomas ^e   Hardisson, David ^f   De Francisco Hernandez, Javier Martin ^g   Lazaro, Jose Miguel ^h   Polo, Luis ⁱ   Riu, Francesc ^j   Rezola, Ricardo ^k   Rojo, Federico ^l   Ruiz, Irune ^m   Hernándiz, Ainoha ^a   De La Camara De Las Heras J M ^b   Coupe, Victoria M ^e  

^a HOSPITAL LLUÍS ALCANYÍS   (Spain)

^b Hospital Universitario de la Ribera   (Algeria)

^c HOSPITAL SAN AGUSTÍN   (Spain)

^d Instituto de Investigación Sanitaria de Navarra   (Spain)

^e University Hospital of Santiago de Compostela   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL VIRGEN DE LA SALUD   (Spain)

^h HOSPITAL OBISPO POLANCO   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^j HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^k Hospital Oncológico de Donosti   (Spain)

^l Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^m Hospital de Donosti   (Spain)

ⁿ Cembimo Biochemical Service   (Spain)

more..

Author keywords

breast cancer; HER2; HistoSonda; immunohistochemistry; in situ hybridization; mRNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA;

ARTICLE; BREAST CANCER; DIAGNOSTIC ACCURACY; DUAL CHROMOGENIC IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENOMIC IN SITU HYBRIDIZATION; HER2 MRNA IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFILTRATING BREAST CARCINOMA; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DIAGNOSTIC ERRORS; FEMALE; HUMANS; IN SITU HYBRIDIZATION; MOLECULAR DIAGNOSTIC TECHNIQUES; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RNA, MESSENGER; SPAIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84861234504     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3182360b0a     Document Type: Article

References (34)

1. Penault-Llorca F, Bilous M, Dowset M, et al. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol. 2009; 132:539-548.
2. Grimm EE, Schmidt RA, Swanson PE, et al. Achieving 95% crossmethodological concordance in HER2 testing: causes and implications of discordant cases. Am J Clin Pathol. 2010;134:284-292.
3. Ross JS. Human epidermlaJ growth factor receptor 2 testing in 2010. DOES chromosome 17 centromere copy number make any difference? Clin Oncol. 2010;28:4293-4295.
4. Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol. 2007;16:207-210. (Pubitemid 350196977)
5. Zhang S, Huang W-C, Li P, et al. Combating tratuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med. 2011;17:461-469.
6. Salmon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science. 1987;235:177-182. (Pubitemid 17231334)
7. Ross JS, Slodkowska E, Symmans WF, et al. The HER2 receptor and breast cancer. Ten years of targeted anti-HER2 therapy and personalized medicine. The Oncologist. 2009;14:320-368.
8. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854. (Pubitemid 34705057)
9. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94:855-857. (Pubitemid 34705058)
10. Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostics markers. J Clin Oncol. 1998;7:1120-1128.
11. Lebeau A, Deimling D, Kaltz C, et al. HER2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001;2:354-363. (Pubitemid 32112846)
12. Hoang MP, Sahin AA, Ordoñez NG, et al. HER2/neu gene amplification compared with HER2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol. 2000;113:852-859. (Pubitemid 33051521)
13. Kay ER, CJ Walsh, Cassidy M, et al. C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol. 1994;47:816-822.
14. Wolf AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor testing in breast Cancer. Arch Pathol Lab Med. 2007;131:18-43. (Pubitemid 46174133)
15. Lal P, Salazar PA, Hudis CA, et al. HER2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2279 cases and comparison of dual-colorans single color scoring. Am J Clin Pathol. 2004;121:631-636. (Pubitemid 38533994)
16. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. (Pubitemid 350003059)
17. Todorovic-Rakovic N, Jovanovic D, Neskovic-Konstantinovic Z, et al. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER2 status in breast cancer. Pathol Int. 2005;55:318-323. (Pubitemid 40910664)
18. Vera-Roman JM, Rubio-Martinez LA. Comapartive assays for the HER2/neu oncogene status in breast cancer. Arch Pathol Lab Med. 2004;128:627-633. (Pubitemid 41490421)
19. García-Caballero T, Grabau D, Green AR, et al. Determination of HER2 amplification in primary breast cancer using dual-colourchromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology. 2010;56:472-480.
20. Bilous M, Dowset M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173-182. (Pubitemid 36245750)
21. Bankfalvi A, Simon R, Brandt B, et al. Comparative methodical analysis of ERBB2/HER2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology. 2000;37:411-419.
22. Syed KM. HER2 Testing. State of the laboratories. Arch Pathol Lab Med. 2010;134:660-662.
23. Kostopoulu E, Vageli D, Kaisaridou D, et al. Comparative evaluation of non-informative HER2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR. Breast. 2007; 16:615-624. (Pubitemid 350154451)
24. McGuire WL. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst. 2002;94:154-155.
25. Raouf E, Grimm EE, Idowu M, et al. Laboratory compliance with the American society of clinical oncology/college of American pathologists guidelines for human epidermal growth factor receptor 2 testing. A college of American pathologists survey of 757 laboratories. Arch Pathol Lab Med. 2010;134:728-734.
26. Leong TY, Leong AS. Controversies in the assessment of HER2. More questions than answers. Adv Anat Pathol. 2006;13:263-269. (Pubitemid 44439981)
27. Ginestier C, Charafe-Jauffret E, Penault-Llorca F, et al. Comaparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol. 2004;202:286-298. (Pubitemid 38325237)
28. Bieche I, Onody P, Tozlu S, et al. Prognostic value of ErBB family mRNA expression in breast carcinomas. Int J Cancer. 2003; 106:758-765. (Pubitemid 36993401)
29. Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, et al. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER2/neu overexpression in human breast carcinomas. Histopathology. 2005;46:431-441. (Pubitemid 40516759)
30. Mrhalova M, Kodet R, Kalinova M, et al. Raltive quatification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB2 protein expression and ERBB2 gene copy number. Pathol Res Pract. 2003;199:453-461. (Pubitemid 37098803)
31. Bofin AM, Ytterchus B, Martin C, et al. Detection and quantitation of HER2 gen amplification and protein expression in breast carcinoma. Am J Clin Pathol. 2004;122:110-119. (Pubitemid 38849881)
32. Vinatzer U, Dampier B, Streubel B, et al. Expression of HER2 and coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res. 2005;11:8348-8357. (Pubitemid 41746947)
33. Labuhn M, Vuaroqueaux V, Fina F, et al. Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR. Int J Biol Markers. 2006;21:30-39.
34. Arribas J, Baselga J, Pedersen K, et al. p95HER2 and breast cancer. Cancer Res. 2011;71:1515-1519.